公开(公告)号：WO2014033235A2

公开(公告)日：2014-03-06

申请号：PCT/EP2013067950

申请日：2013-08-29

Applicant: UNIV ZUERICH

Inventor： KRISHNAN MADHAVI ,  CELEBRANO MICHELE

IPC: G02B26/02

CPC classification number: G02B26/02 ,  B82Y20/00 ,  G02B1/005 ,  G02B26/026 ,  Y10S977/774 ,  Y10S977/932

Abstract: The invention relates to a device for orienting at least one object in at least a first or a second orientation or for placing it in a first or a second spatial location, comprising: a substrate (10) having a surface (10a), at least one object (3) levitated above said surface (10a),wherein the device (1) is designed to generate an e.g. electrostatic potential with help of the substrate (10) for trapping the at least one object (3), the potential having at least a first minimum and a second minimum, so that the at least one object (3) is oriented in the first orientation (or located in a first spatial location) when being trapped in the first minimum, and in the second orientation (or located in the second spatial location) when being trapped in the second minimum, and wherein said at least one object (3) is trapped in one of said minima.

Abstract translation: 本发明涉及一种用于以至少第一或第二取向定向至少一个物体或用于将其放置在第一或第二空间位置中的装置，包括：至少具有表面（10a）的基底（10） 悬浮在所述表面（10a）上方的一个物体（3），其中所述装置（1）被设计成产生例如， 用于捕获所述至少一个物体（3）的用于捕获所述至少一个物体（3）的所述基底（10）的所述静电电势，所述电位具有至少第一最小值和第二最小值，使得所述至少一个物体（3）在所述第一取向 （或位于第一空间位置）当被捕获在第二最小值中时，并且在被捕获在第二最小值中时处于第二方向（或位于第二空间位置中），并且其中所述至少一个对象（3）是 被困在最小的一个中。

公开(公告)号：WO2013007763A9

公开(公告)日：2013-03-21

申请号：PCT/EP2012063617

申请日：2012-07-11

Applicant: UNIV ZUERICH ,  JANKOVIC DRAGANA ,  KISTOWSKA MAGDALENA ,  CONTASSOT EMMANUEL ,  FRENCH LARS E ,  GEHRKE SAMUEL

Inventor： JANKOVIC DRAGANA ,  KISTOWSKA MAGDALENA ,  CONTASSOT EMMANUEL ,  FRENCH LARS E ,  GEHRKE SAMUEL

IPC: C07K16/24 ,  A61K31/64 ,  A61K31/7088 ,  A61P17/10 ,  C07K16/28

CPC classification number: A61K38/2006 ,  A61K31/50 ,  A61K31/64 ,  A61K2039/505 ,  C07K16/245 ,  C07K16/2866 ,  G01N33/6869

Abstract: The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1 beta, IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1 beta, IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1 beta, I L-1 beta receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.

Abstract translation: 本发明提供了能够与解离常数为10-8mol / l的IL-1β，IL-1受体1型，NLRP3，ASC，Caspase-1和组织蛋白酶B结合的炎症小组成员的抑制剂，或 较小的预防和治疗痤疮，特别是抗体，抗体片段，抗体样分子，6至30个氨基酸残基的寡肽，长度为10至75个核苷酸的核酸适体分子或可溶性多肽，其包含 包含IL-1β，IL-1受体1型，IL-1受体2型，NLRP3，ASC和半胱天冬酶-1的成员的蛋白质序列内的至少30个氨基酸的连续氨基酸序列 。 类似地，提供了用于预防或治疗痤疮的干扰RNA或IL-1β，I L-1β受体1型，NLRP3，ASC，Caspase-1和组织蛋白酶B的基因表达的反义调节剂。

公开(公告)号：WO2012164103A9

公开(公告)日：2013-03-21

申请号：PCT/EP2012060533

申请日：2012-06-04

Applicant: UNIV ZUERICH ,  SCHWAB MARTIN ,  TEWS BJOERN ,  KEMPF ANISSA

Inventor： SCHWAB MARTIN ,  TEWS BJOERN ,  KEMPF ANISSA

IPC: A61K31/133 ,  A61K31/138 ,  A61K31/4245 ,  A61K31/661

CPC classification number: A61K31/437 ,  A61K31/135 ,  A61K31/166 ,  A61K31/40 ,  A61K31/402 ,  A61K31/415 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/517 ,  A61K31/52 ,  A61K31/662 ,  A61K31/7105 ,  A61K31/713

Abstract: The present invention provides inhibitors capable of binding to a member of the S1PR receptor group comprised of S1PR2 and S1PR5 with a dissociation constant of 5x10-7 mol/l or smaller for treating neuronal damage, specifically an antibody, an antibody fragment, an antibody-like molecule, a nucleic acid aptamer or an oligopeptide with 6 to 30 amino acid residues in length. Similarly, an interfering RNA or an antisense modulator of gene expression of G13 or a member of the S1PR receptor group described above are provided for treating of neuronal damage.

Abstract translation: 本发明提供能够结合S1PR2和S1PR5的S1PR受体组成员的抑制剂，其解离常数为5×10 -7 mol / l以下，用于治疗神经元损伤，特别是抗体，抗体片段， 类似分子，长度为6至30个氨基酸残基的核酸适体或寡肽。 类似地，提供了用于治疗神经元损伤的干扰RNA或G13基因表达或上述S1PR受体组成员的反义调节剂。

公开(公告)号：WO2012160137A3

公开(公告)日：2013-01-24

申请号：PCT/EP2012059707

申请日：2012-05-24

Applicant: UNIV ZUERICH ,  UNIV ALMERIA ,  ROSENTHAL JOACHIM JAKOB ,  SCHIPANI DAVIDE MOSE ,  LOPEZ-RAMOS JUAN ANTONIO

Inventor： ROSENTHAL JOACHIM JAKOB ,  SCHIPANI DAVIDE MOSE ,  LOPEZ-RAMOS JUAN ANTONIO

IPC: H04L9/08

CPC classification number: H04L9/0819

Abstract: A system, apparatus and method are disclosed for efficient distribution of keys with security information purposes. In one aspect, one apparatus, the key server, is in charge of generating the information that is needed to encrypt the key using an orthogonal decomposition of a vector space and assign information that determine uniquely every authorized user and to distribute the key. In another aspect a plurality of apparatus receive and transmit the encrypted key and, using the information that determines them are able to get the key by means of a scalar product and that allows access to some digital information that can be sent by the key server itself or another server using the encryption key.

Abstract translation: 公开了一种用于有效分发具有安全信息目的的密钥的系统，装置和方法。 在一个方面，密钥服务器的一个装置负责使用向量空间的正交分解来生成加密密钥所需的信息，并且分配唯一确定每个授权用户的信息并分发密钥。 在另一方面，多个装置接收和发送加密的密钥，并且使用确定它们的信息能够通过标量积获得密钥，并允许访问可由密钥服务器本身发送的一些数字信息 或使用加密密钥的另一台服务器。

公开(公告)号：WO2012093127A3

公开(公告)日：2012-10-04

申请号：PCT/EP2012050066

申请日：2012-01-04

Applicant: UNIV ZUERICH ,  CHARITE UNIVERSITAETSMEDIZIN ,  BECHER BURKHARD ,  HEPPNER FRANK

Inventor： BECHER BURKHARD ,  HEPPNER FRANK

IPC: C07K16/18 ,  A61P25/28

CPC classification number: C07K16/244 ,  A61K31/202 ,  A61K31/5377 ,  A61K38/1793 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/92 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2320/30 ,  G01N33/502 ,  G01N33/5058

Abstract: The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like- molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R- ß1, IL-12R-ß2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided.

Abstract translation: 本发明提供了抗p40，IL-12或IL-23的抗体，用于预防或治疗阿尔茨海默氏病。 它进一步提供了一对白细胞介素12或23及其特异性受体，特别是抗体，抗体片段，抗体样分子，用于预防或治疗阿尔茨海默氏病的配体。 类似地，提供了用于预防或治疗阿尔茨海默氏病的p19，p35，p40，IL-12R-β1，IL-12R-β2和/或IL-23R的基因表达的siRNA，反义或转录因子调节剂。

公开(公告)号：WO2012072715A2

公开(公告)日：2012-06-07

申请号：PCT/EP2011071446

申请日：2011-11-30

Applicant: UNIV ZUERICH ,  UNIV BERN ,  ZANGEMEISTER-WITTKE UWE ,  HUWILER ANDREA ,  GRUETTER MARKUS G ,  BOURQUIN FLORENCE

Inventor： ZANGEMEISTER-WITTKE UWE ,  HUWILER ANDREA ,  GRUETTER MARKUS G ,  BOURQUIN FLORENCE

CPC classification number: A61K38/51 ,  A61K31/7088

Abstract: The present invention relates to the use of prokaryotic sphingosine-1 -phosphate lyases (S1PL) and S1PLs that lack a transmembrane domain or of a nucleic acid encoding such an S1PL in the prevention or treatment of a disease condition associated with elevated levels of sphingosine-1 -phosphate (S1P), and for which S1P elevation is directly or indirectly causative. In addition, the invention relates to a new product in the form of S1PL lacking the N-terminal loop domain.

Abstract translation: 本发明涉及原核鞘氨醇-1-磷酸裂合酶（S1PL）和缺乏跨膜结构域的S1PL或编码这种S1PL的核酸在预防或治疗与鞘氨醇 - 1-磷酸（S1P），并且其S1P升高直接或间接成为原因。 此外，本发明涉及S1PL形式的缺乏N端环域的新产物。

公开(公告)号：WO2010046289A3

公开(公告)日：2011-02-17

申请号：PCT/EP2009063406

申请日：2009-10-14

Applicant: UNIV ZUERICH PROREKTORAT MNW ,  HEIKENWAELDER MATHIAS ,  AGUZZI ADRIANO

Inventor： HEIKENWAELDER MATHIAS ,  AGUZZI ADRIANO

IPC: A61K39/395 ,  A61P1/16 ,  A61P31/12 ,  A61P35/00 ,  C07K16/24 ,  C12N15/113

CPC classification number: C07K16/242 ,  A61K2039/505 ,  C07K16/2878 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32

Abstract: The present invention relates to a method of preventing and treating chronic hepatitis and other liver diseases comprising administering a blocker of Light, LTa1ß2, LTa2ß1 or LTßR, and the use of such blockers in said prevention and treatment and in the manufacture of medicaments for preventing and treating chronic hepatitis and other liver diseases.

Abstract translation: 本发明涉及一种预防和治疗慢性肝炎及其他肝病的方法，包括给予Light，LTa1β2，LTa2β1或LTβR的阻断剂，以及在所述预防和治疗和制造用于预防和/ 治疗慢性肝炎等肝病。

公开(公告)号：WO2010103475A3

公开(公告)日：2010-11-25

申请号：PCT/IB2010051038

申请日：2010-03-10

Applicant: MED DISCOVERY SA ,  UNIV ZUERICH ,  FONTANA ADRIANO ,  RECHER MIKE ,  KUNDIG CHRISTOPH

Inventor： FONTANA ADRIANO ,  RECHER MIKE ,  KUNDIG CHRISTOPH

IPC: A61K35/14 ,  A61K38/55 ,  A61P7/00 ,  C12N5/0787 ,  C12Q1/37

CPC classification number: A61K38/57 ,  A61K35/15 ,  A61K35/28 ,  A61K38/1709 ,  A61K2300/00

Abstract: The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.

Abstract translation: 本发明涉及作为丝氨酸蛋白酶抑制剂的治疗化合物，其药物组合物及其在治疗人或动物体中的用途。 更具体地说，本发明涉及一种治疗嗜中性粒细胞减少症的方法，其包括向有需要的受试者施用治疗有效量的丝氨酸蛋白酶抑制剂。 本发明还包括在用于基因治疗的骨髓细胞转染期间和之后预防骨髓细胞（1）的凋亡，（2）在用于重建造血细胞的血液干细胞移动过程中和（3）在髓样细胞输注期间 重建血液造影用于基因治疗或通过输注嗜中性粒细胞治疗中性粒细胞减少症的血统。

公开(公告)号：WO2010106431A3

公开(公告)日：2010-11-18

申请号：PCT/IB2010000597

申请日：2010-03-19

Applicant: LUDWIG INST FOR CANCER RES LTD ,  UNIV OXFORD ,  UNIV ZUERICH ,  RENNER CHRISTOPH ,  WADLE ANDREAS ,  CERUNDOLO VINCENZO ,  STEWART-JONES GUILLAUME ,  JONES E YVONNE

Inventor： RENNER CHRISTOPH ,  WADLE ANDREAS ,  CERUNDOLO VINCENZO ,  STEWART-JONES GUILLAUME ,  JONES E YVONNE

IPC: C07K16/30 ,  A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

CPC classification number: C07K16/30 ,  A61K2039/505 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to NY-ESO- 1 tumor antigen peptide/MHC molecule complexes, particularly in a manner like T cell receptors and with greater affinity than T cell receptors recognizing NY-ESO-I peptide/HLA complexes. These antibodies, particularly human antibodies are useful in the diagnosis and treatment of cancer, including melanoma, lung, esophageal, liver, gastric, prostate, ovarian, bladder and synovial sarcoma. The antibodies and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies T1, T2 and T3 whose sequences are provided herein.

Abstract translation: 结合NY-ESO-1肿瘤抗原肽/ MHC分子复合物的特异性结合成员，特别是抗体及其片段，特别是以类似T细胞受体的方式，并且具有比识别NY-ESO-1肽/ HLA复合物。 这些抗体，特别是人抗体可用于诊断和治疗癌症，包括黑素瘤，肺癌，食管癌，肝癌，胃癌，前列腺癌，卵巢癌，膀胱癌和滑膜肉瘤。 抗体及其片段也可以与化学治疗剂，免疫调节剂或抗癌剂和/或与其它抗体或其片段组合用于治疗。 这种抗体以本文提供其序列的新型抗体T1，T2和T3为例。

公开(公告)号：WO2009092602A8

公开(公告)日：2010-09-02

申请号：PCT/EP2009000439

申请日：2009-01-23

Applicant: UNIV ZUERICH ,  HUANG DANZHI ,  KOLB PETER ,  NEVADO CRISTINA ,  CAFLISCH AMEDEO ,  LAFLEUR KARINE

Inventor： HUANG DANZHI ,  KOLB PETER ,  NEVADO CRISTINA ,  CAFLISCH AMEDEO ,  LAFLEUR KARINE

IPC: C07D487/14 ,  A61K31/519

CPC classification number: C07D473/06 ,  A61K31/522 ,  C07D473/04 ,  C07D487/14

Abstract: The invention relates to compounds of formula 1, tautomers and salts thereof, wherein R1, R2, R3, R4, and R5 have the meanings indicated in the specification. These compounds are receptor tyrosine kinase EphB4 inhibitors useful for the treatment of angiogenesis dependent cancers and intraocular neovascular syndromes. The invention further relates to a method termed ALTA (anchor-based library tailoring) of selecting compounds from a large compound library for screening as EphB4 inhibitors by computational procedures.

Abstract translation: 本发明涉及式1化合物，其互变异构体及其盐，其中R 1，R 2，R 3，R 4和R 5具有说明书中所示的含义。 这些化合物是可用于治疗血管生成依赖性癌症和眼内新生血管综合征的受体酪氨酸激酶EphB4抑制剂。 本发明还涉及一种称为ALTA（基于锚的文库定制）的方法，从大型化合物文库中选择化合物，通过计算程序筛选为EphB4抑制剂。